Novo Nordisk A/S header image

Novo Nordisk A/S

NOVO B

Equity

ISIN DK0062498333 / Valor 129508879

Nasdaq Copenhagen Equities (2024-09-18)
DKK 882.20-2.35%

Novo Nordisk A/S
UMushroom community rating:

star star star star star
5.00 1 votes No rating yet
NegativeNeutralPositive

About company

Novo Nordisk A/S is a global healthcare company founded in 1923 and based in Denmark. The company is known for its focus on diabetes care and has a long history of innovation in this field. The Novo Nordisk Way, which outlines the company's values and behaviors, is inspired by the vision of its founders to make a difference in diabetes treatment. Today, Novo Nordisk continues to be a leader in diabetes management, as well as in other areas of healthcare.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results (20.08.2024):

Q1 2024 Revenue

Novo Nordisk A/S reported its financial results for the first quarter of 2024, showing a significant increase in revenue. The company achieved a total revenue of DKK 45 billion, marking a 12% growth compared to the same period in the previous year.

Q1 2024 Net Profit

In the first quarter of 2024, Novo Nordisk A/S's net profit rose to DKK 12 billion. This represents a 15% increase from the first quarter of 2023, driven by strong sales performance and cost management.

Q1 2024 Sales Performance

Novo Nordisk A/S experienced robust sales growth in the first quarter of 2024, particularly in its diabetes and obesity care segments. Sales in these areas grew by 14%, contributing significantly to the overall revenue increase.

Q1 2024 Earnings Per Share

The earnings per share (EPS) for Novo Nordisk A/S in the first quarter of 2024 were reported at DKK 5. This is an improvement from DKK 4.30 in the same quarter of the previous year, reflecting the company's strong financial performance.

Q1 2024 Dividend Announcement

Following the strong financial results for the first quarter of 2024, Novo Nordisk A/S announced an interim dividend of DKK 3 per share. This decision underscores the company's commitment to returning value to its shareholders.

Summarized from source with an LLMView Source

Key figures

35.6%1Y
174%3Y
410%5Y

Performance

30.7%1Y
29.7%3Y
27.5%5Y

Volatility

Market cap

448352 M

Market cap (USD)

Daily traded volume (Shares)

1,896,932

Daily traded volume (Shares)

1 day high/low

896.4 / 881

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

5.00

1 votes
Performance:
starstarstarstarstar
5.00
Innovation:
starstarstarstarstar
5.00
Society:
starstarstarstarstar
5.00
Nature:
starstarstarstarstar
4.00
Daniela Gie
Germany, 13 Jun 2024
star star star star star
Most valuable company in the EU (550 billion). Ozempic is likely to help with weight problems, improve kidney function& prevent kidney disease, and is the leading diabetes med https://www.unsw.edu.au/newsroom/news/2024/05/Diabetes-medication-semaglutide-found-to-reduce-risk-of-kidney-disease-and-dea

EQUITIES OF THE SAME SECTOR

AEVIS VICTORIA SA
AEVIS VICTORIA SA AEVIS VICTORIA SA Valor: 47863410
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
2.19%CHF 14.00
Spexis Ltd
Spexis Ltd Spexis Ltd Valor: 10621379
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
11.76%CHF 0.057
Laboratorios Farmaceuticos Rovi, SA
Laboratorios Farmaceuticos Rovi, SA Laboratorios Farmaceuticos Rovi, SA Valor: 3591807
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.07%EUR 73.95
Ionis Pharmaceuticals Inc
Ionis Pharmaceuticals Inc Ionis Pharmaceuticals Inc Valor: 30877188
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
2.05%USD 42.36
Roche Holding Ltd
Roche Holding Ltd Roche Holding Ltd Valor: 1203204
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.83%CHF 268.40
Novartis Inc
Novartis Inc Novartis Inc Valor: 1200526
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.01%CHF 98.04
Roche Holding Ltd
Roche Holding Ltd Roche Holding Ltd Valor: 1203211
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.42%CHF 286.80
Alcon Inc.
Alcon Inc. Alcon Inc. Valor: 43249246
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.71%CHF 81.58
Straumann Holding Ltd
Straumann Holding Ltd Straumann Holding Ltd Valor: 117544866
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.47%CHF 125.85
Sonova Holding Ltd.
Sonova Holding Ltd. Sonova Holding Ltd. Valor: 1254978
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-2.29%CHF 295.00